Overview

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine